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Available online 24 August 2005Even though the idea that amyloid B peptide accumulation is the
primary event in the pathogenesis of Alzheimer’s disease has become
the leading hypothesis, the causal link between aberrant amyloid
precursor protein processing and tau alterations in this type of
dementia remains controversial. We further investigated the role of
B-amyloid production/deposition in tau pathology and neuronal cell
death in the mouse brain by crossing Tg2576 and VLW lines expressing
human mutant amyloid precursor protein and human mutant tau,
respectively. The resulting double transgenic mice showed enhanced
amyloid deposition accompanied by neurofibrillary degeneration and
overt neuronal loss in selectively vulnerable brain limbic areas. These
findings challenge the idea that tau pathology in Alzheimer’s disease is
merely a downstream effect of amyloid production/deposition and
suggest that reciprocal interactions between B-amyloid and tau
alterations may take place in vivo.
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(Hardy and Higgins, 1992; Selkoe, 1991). According to this theory,
neurofibrillary tangle (NFT) formation and the loss of neurons and
synapses in vulnerable regions that invariably accompanies Ah
deposition in the human AD brain are said to be downstream
events resulting from an imbalance between Ah production and
Ah clearance.
The discovery of AD-causing mutations in the amyloid
protein precursor (APP) and the presenilins 1 and 2 genes, along
with the finding that all of these genetic defects enhance the
proteolytic processing of APP to form Ah, is probably the
strongest evidence favoring the amyloid cascade hypothesis
(reviewed in (Selkoe, 1997)).
The recent finding that active immunization against h-amyloid
is associated with a reduction of amyloid deposits, neuritic
pathology and gliotic changes in human AD brains provides
further evidence for the validity of the amyloid cascade hypothesis
(Hardy and Selkoe, 2002), even though at this point very important
safety issues regarding this therapeutic approach need to be
addressed (Schenk, 2002).
A role for Ah in neurofibrillary degeneration is also supported
by recent findings showing that coexpression of human mutant tau
and APP in the mouse brain results in increased NFT formation,
whereas amyloid deposition remains essentially unaltered (Lewis
et al., 2001). Moreover, intracerebral injection of fibrillar Ah42 in
P301L mutant tau transgenic (Tg) mice caused a fivefold increase
in the number of NFT, favoring the hypothesis that fibrillar Ah can
accelerate NFT formation in vivo (Gotz et al., 2001).
All together, the above findings suggest that altered APP
processing would precede tau alterations in the pathogenesis of
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specific neurotoxic species of Ah and its effects on neuronal
function in vivo have not been defined.
We have had the opportunity to further study the in vivo
interactions between Ah production/deposition and tau phospho-
rylation/neurofibrillary degeneration in the mouse brain by
creating a new double transgenic line termed APPsw-tauvlw
obtained by crossing Tg2576 and VLW lines expressing human
APP harboring the double Swedish mutation (APPswe) and
human 4-repeat tau containing a triple mutation (G272V, P301L
and R406W), respectively. In brief, Tg2576 line overexpresses
human APP containing the double Swedish mutation K670N-
M671L in a C57Bl6jxSJL background. Tg2576 mice develop
cerebral Ah deposits and spatial memory deficits in an age-
dependent manner but no neurofibrillary tangle formation or
significant neuronal loss in CA1 (Hsiao et al., 1996; Irizarry et
al., 1997). VLW line overexpresses three tau mutations (G272V,
P301L and R406W) in a C57Bl6jxCBA background. Immuno-
histochemical analysis of VLW brains reveals high human mutant
tau expression in neuronal cell bodies and neurites in cortex and
hippocampus with minimal expression in spinal cord. Ultra-
structural analysis shows a pretangle appearance in neurons
expressing mutant tau, with tau filaments and increased numbers
of lysosomes displaying aberrant morphology similar to that
found in human AD brains (Lim et al., 2001). The biochemical
study of tau phosphorylation and aggregation patterns in the
double mutant APPsw-tauvlw line demonstrates an increase in tau
phosphorylation at non-proline directed sites and tau aggregation
in the double mutant APPsw-tauvlw line in comparison to APPsw
and tauvlw parental lines, respectively, as we have recently
published elsewhere (Perez et al., 2005). Here, we have further
characterized the clinicopathological phenotype of this new
transgenic mouse model.Materials and methods
Transgenic mice
The progeny obtained by crossing Tg2576 and VLW lines
included double mutant APP/tau+/+ (hereafter termed APPsw-
tauvlw), mutant APP+/ (APPsw), mutant tau/+ (tauvlw), and non-
transgenic/ animals.
Spatial reference learning and memory testing (Morris water maze)
Groups of 10–15 Tg+/+(APPsw-tauvlw), Tg+/(APPsw), Tg/+
(tauvlw) and Tg/ littermates underwent spatial reference learning
and memory testing in the Morris watermaze at 9 and 16 months of
age (Go´mez-Isla et al., 2003). The maze was a circular pool
(diameter 1.45 m) filled with water at 20-C. The mice underwent
visible-platform training for 3 consecutive days (8 trials/day) using
a platform raised above the water. This was followed by hidden-
platform training, during which the mice were trained to locate a
platform submerged 1 cm beneath the surface for 9 consecutive
days (4 trials/day). Each trial was terminated when the mouse
reached the platform or after 60 s, whichever came first. Twenty-
four hours after the 12th, 24th and 36th trials, the mice were
subjected to a probe trial in which they swam for 60 s in the pool
with no platform. Trials were recorded using an HVS watermaze
program for analysis of scape latencies and percent time spent ineach quadrant of the pool during probe trials (analysis program
Ethovision, Wageningen, The Netherlands).Neuropathological analysis
Tissue preparation
The mice were sacrificed under CO2 and brains were removed
and snapfrozen in dry ice. For immunohistochemistry, mice were
perfused transcardially with 4% paraformaldehyde; brains were
fixed for 24h in 4% paraformaldehyde in phosphate buffered saline
(PBS), pH 7.4, and coronally sectioned at 30 Am on a freezing
sledge microtome. Groups of 5–7 Tg+/+(APPsw-tauvlw), Tg+/
(APPsw), Tg/+(tauvlw) and Tg/ littermates were studied at 9 and
16 months. Groups of 2–3 Tg+/+( APPsw-tauvlw), Tg/+(tauvlw) and
Tg/ littermates were studied at 25 months.
Immunostaining
30 Am coronal sections were permeabilized with 0.5% Triton-
X100 in PBS, blocked with bovine serum albumin (BSA), and
sequentially probed with primary antibody (4G8 and 6E10 mouse
anti-Ah 1:500, Chemicon, Temecula, CA; AT8 mouse anti-human
PHF tau 1:50, Innogenetics, Belgium) and the appropriate
secondary antibody (anti-mouse IgG1 1:200, Southern Biotechno-
logy, Birmingham, AL; Vector ABC Kit). Sections were processed
by Nissl staining for neuronal counts, Thioflavin-T and modified
Bielschowsky.
Electron microscopy
AT-8 immunostained sections were postfixed in 2% OsO4 for
1 h, embedded in araldite and flat-mounted in formvard-coated
slides. After polymerization, selected areas were trimmed, reem-
bedded in araldite, resectioned in ultrathin sections and examined
in a 100-kV Jeol electron microscope without heavy metal staining.
Amyloid burden quantification
Amyloid deposition was quantified using Ah immunostaining
(monoclonal anti-Ah 4G8 and hrp-anti-mouse) and the anaLYSIS
image system (Gomez-Isla et al., 1996; Irizarry et al., 1997). Video
images were captured of each region of interest on 30 Am sections,
and a threshold of optical density was obtained that discriminated
staining from background. Manual editing eliminated artefacts.
The ‘‘amyloid burden’’, defined as the total percentage of cortex
covered by amyloid deposits over three sections, was calculated for
CA1, cingulate, dentate gyrus molecular layer, entorhinal cortex
(EC), and motor, olfactory and visual cortices.
Stereological neuron counts
Neuron counts were performed in the CA1 hippocampal
subfield, cingulate cortex and EC using the optical dissector
technique (West and Gundersen, 1990) in 30 Am Nissl stained
coronal sections at equally spaced intervals (450 Am), excluding
neurons in the superficial plane of section. The entire volume of
each region of interest was estimated according to the principle of
Cavalieri, using the C.A.S.T Grid System (Olympus, Albertslund,
Denmark).
The CA1 hippocampal subfield was sampled from its caudal
extent anteriorly (Bregma 3.40 to Bregma 1.46) using 50
optical dissectors in each case.
The margins of the lateral EC were defined as follows: caudal,
Bregma 3.88; rostral, Bregma 3.16; lateral, rhinal fissure; and
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in the entire region was estimated using 30 optical dissectors in
each case.
The cingulate cortex was sampled in a caudal-to-rostral
orientation: caudal, section containing the most caudal extent of
the dentate gyrus (Bregma 3.64); rostral, extending anteriorly
0.94 mm (Bregma 2.70); medially, presubiculum; and laterally,
visual cortex. The total number of neurons was estimated using 60
optical dissectors in each case.
The average coefficient of error from the sampling technique
was <0.04 suggesting that a minimal amount of variance observed
in the counts is due to variance from the technique.
Statistical analysis
A mixed multifactorial ANOVA with one within subject factor
(day) and three between subject factors (age, gender and transgenic
status) for repeated measures was conducted to analyze perform-
ances on the Morris watermaze test. Three-way analyses of
variance (ANOVA) were carried out to examine main effects and
all two-way possible interactions of age, gender and transgenic
status on number of neurons and amyloid burden. A Scheffe´ test
was used for post hoc analyses in the absence of interactions.Fig. 1. Morris watermaze performance at 9 (A–C) and 16 months of age (D–F). A
latencies on day 1 of the visible platform training when compared to tauvlw or non
among groups during any of the 9 days of invisible platform training (B) or the thre
significantly longer scape latencies on days 1 and 2 of the visible platform (D), and
non-transgenic littermate controls (E). APPsw-tauvlw and APPsw mice performed sig
15-s probe trials (F). *P < 0.05, **P < 0.01.ANOVA test was used to test for single effects when significant
interactions could be demonstrated. In all tests, the level of
significance was at P < 0.05. Data are presented as mean T
standard error, unless otherwise indicated.Results
The levels of mutant APP and tau in APPsw-tauvlw adult mice (9
months of age) were comparable to APPsw and VLW parental lines,
respectively, as determined by Western blot analysis on brain
homogenates (data not shown).
Behavioral testing
To assess spatial reference learning andmemory function, groups
of 10–15 Tg+/+(APPsw-tauvlw), Tg+/(APPsw), Tg/+(tauvlw) and
Tg/ littermates underwent testing in the Morris watermaze at 9
and 16 months of age. All mice were tested in a coded manner.
A mixed multifactorial ANOVA showed no significant inter-
actions or main effects of age or gender but a significant effect of
transgenic status on the Morris watermaze test performance (visible
platform P < 0.05, invisible platform P < 0.05 and probe trials P <t 9 months, APPsw-tauvlw and APPsw mice showed significantly longer scape
-transgenic littermate controls (A). No significant differences were detected
e 15-s probe trials (C). At 16 months, APPsw-tauvlw and APPsw mice showed
multiple days of the invisible platform training, when compared to VLWor
nificantly worse than tauvlw or non-transgenic littermate controls in the three
Fig. 2. Stereologically-based neuron counts in the CA1 subfield of the
hippocampus, cingulate cortex and EC at 9 (A) and 16 months of age (B).
At 9 months, APPsw-tauvlw mice showed significant neuronal loss limited to
the EC region by 19% when compared to the other three groups (84,283 T
4050 APPsw-tauvlw vs. 100,644 T 4529 APPsw, 99,399 T 4249 tauVLW and
103,606 T 3412 non-transgenic littermates). No significant loss of neurons
could be demonstrated in any of the regions assessed in APPsw or tauVLW
mice in comparison to non-transgenic littermate controls at this same age
(A). At 16 months, neuron counts in the EC and CA1 hippocampal region
showed a pronounced neuronal loss in APPsw-tauvlw brains by 36% in
comparison to the other three groups while no significant neuronal loss
could be detected in similarly aged APPsw or tauvlw brains in any of the
regions examined (EC: 76,508 T 3798 APPsw-tauvlw vs. 105,622 T 5927
APPsw, 116,818 T 5909 tauvlwC, and 119,769 T 7989 non-transgenic
littermates; CA1 hippocampal subfield: 61,135 T 5669 APPsw-tauvlw vs.
82,842 T 4981 APPsw, 87,684 T 5463 tauvlw and 95,949 T 4103 non-
transgenic controls) (B). *P < 0.05, **P < 0.01.
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significantly longer scape latencies for APPsw-tauvlw and APPsw
mice when compared to tauvlw and non-transgenic littermates on
day 1 of the visible platform training (P = 0.002) (Fig. 1A).
However, no significant differences could be demonstrated on days
2 (P = 0.35) or 3 (P = 0.15) of the visible platform training, the 9
days of invisible platform training (P = 0.93) (Fig. 1B), or the three
60-s probe trials administered (P = 0.81). It has been previously
suggested that the sensitivity of this test can be increased by
giving shorter probe trials (Gerlai, 2001). Thus, in an attempt to
detect subtle spatial memory impairment, we analyzed the
performance of mice during the first 15 s of every probe trial.
Again, no significant differences could be demonstrated among
genotypes at this age (P = 0.34) (Fig. 1C).
At 16 months, a Scheffe´ test showed that APPsw-tauvlw and
APPsw mice performed significantly worse than similarly aged non-
transgenic littermate controls with longer scape latencies onmultiple
days of the visible (P < 0.01) (Fig. 1D) and invisible platform
training (P < 0.05) (Fig. 1E), and spent lower percent of time in the
correct quadrant of the pool during the probe trials (P < 0.01) (Fig.
1F). Interestingly, tauvlw mice did not show impairment in this test
up to 16 months when compared to non-transgenic littermate
controls, suggesting that mutant tau overexpression in this Tg line
does not in itself cause spatial reference memory alteration.
Neuropathological assessment
At 9 months, Ah immunostaining using the monoclonal
antibodies 4G8 and 6E10 demonstrated only scarce amyloid
deposits in the APPsw-tauvlw brains beginning in the cingulate,
motor and entorhinal cortices. The morphology, amount and pattern
of regional distribution of the amyloid deposits at this age were
comparable to those seen in APPsw mice. As expected, no Ah
immunoreactivity was found in tauvlw or non-transgenic littermate
controls. As with tauvlw mice, at 9 months APPsw-tauvlw developed
intracytoplasmic straight tau filaments composed of abnormally
hyperphosphorylated tau in cortex and hippocampus, becoming
consistently present and numerous only in older animals (Lim et al.,
2001; Perez et al., 2005). Of note, the ultrastructural study of
sarkosyl insoluble tau aggregates from these mice shows that tau
filaments are noticeably wider in APPsw-tauvlw (about 10 nm in
diameter) than in tauVLW brains (about 2 nm in diameter), as we have
recently published elsewhere (Perez et al., 2005). However, no overt
NFT formation could be demonstrated at this age.
Stereologically-based neuron counts were carried out in the CA1
subfield of the hippocampus, cingulate cortex and EC. We
concentrated on these regions for neuronal counts because they
undergo early amyloid deposition in both transgenic mice and
human AD brains and they show marked neuronal loss in humans
with AD. A three-way ANOVA showed no significant interactions
or main effects of age or gender on total number of neurons but a
significant interaction of age and transgenic status on EC and CA1
neuronal counts (P = 0.045 and 0.025, respectively). The ANOVA
by genotype post hoc analysis at 9 months, showed a significant
neuronal loss limited to the EC region of APPsw-tauvlw mice by 19%
when compared to the other three groups (P  0.001) (84,283 T
4050 APPsw-tauvlw vs. 100,644 T 4529 APPsw, 99,399 T 4249 tauvlw
and 103,606 T 3412 non-transgenic littermates) (Fig. 2A). No
significant loss of neurons could be demonstrated in any of the
regions assessed in APPsw or tauvlw brains compared to similarly
aged non-transgenic littermate controls.At 16 months, a two-way ANOVA demonstrated significant
main effects of gender (P < 0.03) and genotype (P < 0.03) as well
as an interaction between these two factors (P < 0.04) on amyloid
deposition in the majority of regions examined. Ah immunostain-
ing demonstrated up to a fivefold increase in the amount of
amyloid deposition in some regions in APPsw-tauvlw brains in
comparison to similarly aged Tg2576 mice (Fig. 3A). The
difference was statistically significant in every region assessed
(ANOVA P = 0.001 cingulate cortex, P = 0.025 dentate gyrus
molecular layer, P < 0.001 motor cortex, P = 0.007 olfactory
cortex and P < 0.001 visual cortex) except for the CA1
hippocampal subfield (P = 0.336). Interestingly, we observed a
very prominent gender difference in the amount of amyloid
deposits both in APPsw and APPsw-tauvlw lines. In particular,
APPsw-tauvlw female mice demonstrated significantly higher
amyloid burdens in every region examined except for CA1 when
compared to APPsw-tauvlw males (P < 0.01) (Fig. 3B). At this age,
many of the amyloid deposits in APPsw-tauvlw brains were
surrounded by abnormally phosphorylated tau-containing punctate
neurites, as demonstrated by AT8 immunostaining, but as for
younger mice, no tangle formation could be seen.
At 16 months, neuron counts in the EC and CA1 hippo-
campal region, but not in the cingulate cortex, showed a
Fig. 3. Amyloid burden quantitation. At 16 months of age, amyloid burden
is increased up to fivefold in APPsw-tauvlw brains (N = 7, 4 F and 3 M) in
comparison to similarly aged APPsw mice (N = 7, 3 F and 4 M). The
difference is significant in every region assessed except for the CA1
hippocampal subfield (A). At the same age, APPsw-tauvlw female mice
demonstrated significantly higher amyloid burdens than APPsw-tauvlw
males (B). F: female, M: male. *P < 0.05, **P < 0.01.
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comparison to similarly aged non-transgenic littermate controls
(P < 0.001), while no significant neuronal loss could be detectedFig. 4. Photomicrographs of Nissl-stained 30 Am thick sections through the hippoca
loss of neurons in these two regions in an APPsw-tauvlw 16-month-old mouse (A an
indicate areas of massive neuronal depopulation occupied by amyloid deposits. Sin APPsw or tauvlw brains in any of the regions examined (EC:
76,508 T 3798 APPsw-tauvlw vs. 105,622 T 5927 APPsw, 116,818 T
5909 tauvlw, and 119,769 T 7989 non-transgenic littermates; CA1:
61,135 T 5669 APPsw-tauvlw vs. 82,842 T 4981 APPsw , 87,684 T
5463 tauvlw, and 95,949 T 4103 non-transgenic controls) (Figs. 2B
and 4). In addition, very intense astrocytosis and microgliosis
could be seen in areas with abundant amyloid deposits and
neuronal loss such as the EC and CA1 in APPsw-tauvlw aged mice.
Interestingly, no correlation was found between amyloid burden
and the amount of neuronal loss at any of the ages or regions
examined (data not shown).
When we examined APPsw-tauvlw brains at 25 months, two
important features were noted: (1) increased amount of abnormal
neurites containing phosphorylated tau in the vicinity of plaques,
most of them showing coarse and varicose profiles, and (2) NFT-like
structures AT8 and Thioflavin-T positive in the EC region (Fig. 5).
Modified Bielschowsky silver stain further demonstrated dystrophic
neurites surrounding amyloid plaques and typical NFTs in the EC
and, to a lesser degree, in the CA1 area of the hippocampus (Fig. 5).
Together, these abnormalities resemble the neuropathological
features of senile plaques and NFTs found in conventional AD
(Duyckaerts and Dickson, 2003). Electron microscopy studies of
AT8 immunostained sections from APPsw-tauvlw mice at this
advanced age showed abundant enlarged degenerating neurites in
the periphery of amyloid plaques (Figs. 6A and B). These
degenerating neurites were filled with irregular dense bodies that
appeared membrane limited in many cases. Some of these enlarged
degenerating neurites showed strong AT-8 immunoreactivity in the
irregularly shaped dense bodies as well as in both granular and
fibrillar structures present among the dense bodies. Moreover,
abundant AT-8 positive neurites filled with immunopositive
filaments surrounded the giant amyloid plaques (Figs. 6B–D). In
most cases, bundles of amyloid filaments were located adjacent to
degenerating neurites filled with dense bodies and also adjacent tompal formation (A and B) and entorhinal cortex (C and D) showing marked
d C) in comparison to a similarly aged APPsw littermate (B and D). Arrows
cale bars A–D, 200 Am.
Fig. 5. 25 month-old APPsw-tauvlw mice showing thioflavine positive plaques and scarce neurons (arrows) (A), AT8-immunoreactive neurons and cellular
processes (B), dystrophic neurites surrounding amyloid cores, and neurons with NFT-like structures stained with the Bielschowsky method (C, D). At high
magnification, dystrophic neurites of amyloid plaques show varicose or curb-shaped terminal processes (E) similar to those encountered in human AD brains.
Neurons containing NFTs exhibit typical flame-shaped fibrillar inclusions (F–H) resembling NFTs in human AD. Scale bars, A—20 Am; B—40 Am; C–D, bar
in D—25 Am; E–H, bar in H—10 Am.
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filaments were found in apical dendrites of otherwise healthy
appearing neurons (Fig. 6A).Discussion
The results of this study show that coexpression of human
mutant APP and human mutant tau enhances widespread Ah
deposition and triggers neurofibrillary degeneration and neuronal
loss in selective vulnerable brain limbic areas in the double mutant
APPsw-tauvlw mouse model.
To date, two other Tg mouse models coexpressing mutant
APP and tau have been reported (Lewis et al., 2001; Oddo etal., 2003). Female TAPP mice showed enhanced neurofibrillary
pathology in the limbic system and olfactory cortex at 9 to 11
months of age as compared to mice overexpressing mutant tau
alone, while the structure and number of amyloid plaques
remained comparable to their parental strain Tg2576 (Lewis et
al., 2001). The triple Tg model published by Oddo and
coworkers based on comparable overexpression of mutant
human APP, PS1 and tau develops early deficits in long-term
synaptic plasticity that correlate with accumulation of intra-
neuronal Ah followed by amyloid plaques and NFT formation
in an age-dependent fashion (Oddo et al., 2003). Interestingly,
extracellular Ah deposition precedes tau pathology by several
months in this latter Tg line, favoring the amyloid cascade
pathogenic hypothesis.
Fig. 6. Electron micrographs from AT-8 immunostained sections of cerebral cortices of 25 month-old APPsw-tauvlw mice. Apical dendrite of an AT8-positive
neurone (N) located at the peripheral area of an amyloid plaque, showing immunoreactive filaments (arrowheads) and surrounded by unlabeled degenerated
processes filled with dense bodies (white arrows) (A). Peripheral area of another amyloid plaque with bundles of amyloid fibrils (arrowheads) in the vicinity of
both AT8-positive neurites (black arrows) and unlabeled degenerated processes filled with dense bodies (white arrows). M: microglial cells (B). AT8-positive
neurite (arrowheads) closely surrounded by abundant bundles of amyloid fibrils (arrows) (C). Higher magnification of the AT8-positive neurite framed in C,
showing immunolabeled neurofibrillary degeneration (arrowheads) adjacent to bundles of amyloid filaments (arrows) (D). Calibration bars: 2 Am in A and B, 1
Am in C and 2.6 Am in D.
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Tg model that overexpresses APPsw and a triple FTDP-17 tau
mutation (APPsw-tauvlw). We have recently presented elsewhere
biochemical evidence of enhanced phosphorylation at non-proline
directed phosphorylation (NPDP) sites such as serine 262 in APPsw-
tauvlw mice in comparison to APPsw mice (Perez et al., 2005). In
addition, we observed an increase of the amount of sarkosyl
insoluble tau polymers in the double mutants forming tau filaments
that are wider in diameter in APPsw-tauvlw mice (about 10 nm) when
compared to tauvlw mice (about 2 nm) (Perez et al., 2005). All
together, these findings suggest that Ah facilitates phosphorylation
of tau at NPDP sites and tau polymerization in these mice (Perez et
al., 2005). In the present study, the neuropathological assessment
showed a significant increase in the amount of amyloid deposition in
cortical and limbic areas of APPsw-tauvlw as compared to APPsw
mice, and a significant neuronal loss in selective vulnerable areas
like the entorhinal cortex and CA1 subfield of the hippocampus,
increasing in an age-dependent fashion up to 36% at 16 months. In
addition to enhanced Ah pathology and cell loss, coexpression of
human mutant APP and tau in APPsw-tauvlw mice not only resulted
in increased tau phosphorylation but also triggered NFT-likeformation in the EC and CA1 regions at 25 months of age. These
results serve to confirm previous observations of enhanced tau
pathology in mice coexpressing mutant APP and tau in their brains
(Lewis et al., 2001; Oddo et al., 2003). However, the substantial
increase of Ah pathology observed in APPsw-tauvlw mice in
comparison to their parental line APPsw challenges the idea that
tau pathology in AD merely stems from amyloid production/
deposition, and favors a model in which both h-amyloid and tau
pathology can be enhanced by the presence of each other.
The variability noted in the different transgenic mouse models
may be influenced by the specific mutation, promoter, expression
levels and/or mouse genetic background. In fact, the available data
do not differentiate the relative contribution of specific tau
mutations to the accelerated amyloid deposition and neuronal loss
observed in the APPsw-tauvlw brains. The most parsimonious
explanation of the accelerated amyloid deposition and cell death
seen in the APPsw-tauvlw mouse model would be that it merely
stems from artificially high levels of protein expression.
Interestingly, the amount of Ah pathology is markedly
influenced by mouse gender, with up to fivefold higher amyloid
burdens in APPsw-tauvlw female mice in comparison to male mice.
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(APPsw) (Callahan et al., 2001), points to the importance of gender
in amyloid production/deposition and highlights the need to take
this variable into account in the design of studies carried out on
these mice, and possibly on other Tg mouse models of brain
amyloidogenesis (Wang et al., 2003).
The exact mechanisms involved in the accelerated amyloid
deposition and neuronal death in the APPsw-tauvlw mouse model
need now to be clarified. It has been previously shown that mutant
tau overexpression in the tauvlw line results in lysosomal
abnormalities including increased numbers of lysosomes display-
ing aberrant morphology (Lim et al., 2001) that mimic those found
in human AD brains (Cataldo et al., 1994, 1996). Thus, it is
possible that a failure in the endosome-lysosomal machinery could
enhance the imbalance between Ah production and Ah clearance
in APPsw-tauvlw mice, accounting, at least in part, for the increase
of Ah pathology observed in their brains. Of note, Vitali et al.
(2004) have recently reported significant increases in the amount of
soluble Ah species in brains from patients with FTDP-17 in
comparison to frontotemporal dementia lacking distinctive histo-
pathology or normal controls.
Interestingly, cell death in APPsw-tauvlw mice preceded overt
amyloid plaque formation and NFT formation and did not correlate
with amyloid burden in any of the regions examined. Thus, it
seems unlikely that neuronal death in the APPsw-tauvlw line results
from enhanced amyloid deposition, although at this point a
deleterious effect of soluble or prefibrillar Ah species on neuron
survival in these mice cannot be ruled out.
Learning and memory deficits, as measured by the Morris
watermaze test, were quite modest at 9 months of age despite
incipient amyloid deposits in APPsw-tauvlw and APPsw brains, and
significant neuronal loss in the EC in the former. By 16 months,
however, both APPsw and APPsw-tauvlw mice showed marked
spatial reference memory impairment compared to tauvlw and non-
transgenic littermate controls.
Thus, coexpression of human mutant APP and tau in the
APPsw-tauvlw mouse model enhanced both Ah and tau pathology
and resulted in significant neuronal loss in selective vulnerable
brain areas, providing a new in vivo model that mimics, to a
remarkable extent, the human AD phenotype. We believe this new
line of mice represents a very valuable tool for further study of
the pathogenetic mechanisms involved in AD and, more
importantly, for testing therapies potentially able to interfere with
Ah and tau pathology and/or to prevent neuronal death. Overall,
our results highlight the need for future therapies able to tackle
both amyloid production/deposition and tau pathology, in order to
successfully halt and/or reverse the pathology and cognitive
decline in AD. Supporting this notion, two recent autopsy reports
from AD patients who underwent experimental Ah immunization
found a significant decrease in the amount of amyloid deposits in
certain brain areas but also showed the presence of additional
damage including tau pathology and synapse and neuronal loss
that may be irreversible by attacking exclusively h-amyloid
(Ferrer et al., 2004; Nicoll et al., 2003). Keeping in mind that
humans and mice differ from each other in many ways, and that
some of the results from the presently available animal models for
AD should be interpreted with caution, our results serve to
challenge the idea that tau pathology in AD is merely a downstream
effect of amyloid production/deposition, and they suggest that
reciprocal interactions between h-amyloid and tau may take place
in vivo.Acknowledgments
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